Additionally, due to its encouraging results in phase I trials in multiple cancer types, the limited efficiency of VEGFR inhibitors as montherapy [223], the involvement of MET in the resistance to vemurafenib in BRAF mutated melanoma [163,224] and the importance of a dual targeting of MET and VEGFR, a randomized phase II trial of cabozantinib in metastatic melanoma was launched and showed clinical benefit independent of BRAF mutation status but was discontinued because it was underpowered to draw conclusions (Table 9) [181]. This evidence concerns the gene KDR and cancer.